Letaplimab represents a novel clinical strategy for treating complement-mediated diseases. This antibody targets complement component C1q, a essential factor of the complement system, aiming to inhibit its first https://nicolasnwxz554625.blognody.com/50271788/letaplimab-a-new-clinical-approach